title: [Experience in the use of polyosm in the treatment of edematous maculopathy].
abstract: The efficiency and tolerability of using a new osmotic diuretic, i.e. polyosm (a solution of polyethylene oxide 400 for the intravenous administration), was studied in patients with edematous maculopathy of different geneses. The drop-by-drop introduction of polyosm, 200 ml (the dose amounted to 0.8-1 g/kg in terms of polyethylene oxide 400), one per day and during 3 days, proved the efficiency of the preparation as a corrector of edematous maculopathy, which was confirmed by an involution of the eye-tissue edema, reduced sizes of the central scotoma, and by an improved visual acuity. The tolerability of the course-based administration of polyosm by patients was found to be good and satisfactory. No negative impact produced by the preparation on the indices of central hemodynamics was detected; the hypotensive effect of polyosm was found, as a normalized level of the systolic and diastolic pressure, only in patients with an originally high arterial pressure. Hypokalemia was, after the course-based use of polyosm, of a moderate nature.
authors.forename: M B
authors.initials: MB
authors.lastname: Plotnikov
authors.forename: O G
authors.initials: OG
authors.lastname: Shilova
authors.forename: N Iu
authors.initials: NIu
authors.lastname: Khatminskiĭ
authors.forename: I V
authors.initials: IV
authors.lastname: Zapuskalov
authors.forename: A A
authors.initials: AA
authors.lastname: Fetisov
authors.forename: S V
authors.initials: SV
authors.lastname: Filippova
authors.forename: N A
authors.initials: NA
authors.lastname: Baliuk
authors.forename: Iu F
authors.initials: IuF
authors.lastname: Khatminskiĭ
authors.forename: M P
authors.initials: MP
authors.lastname: Pronin
authors.forename: N F
authors.initials: NF
authors.lastname: Fedorova
mesh_terms: D000328:Adult; D000368:Aged; D003627:Data Interpretation, Statistical; D004234:Diuretics, Osmotic / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007275:Injections, Intravenous; D008266:Macula Lutea; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000627:therapeutic use*; D012164:Retinal Diseases / Q000188:drug therapy*; D014792:Visual Acuity
chemical_list: D004234:Diuretics, Osmotic; D011092:Polyethylene Glycols